GlassScriptPhysician profile
Stuart Andrew Friedman
NPI 1780749481
$2,255.23
in general payments reported to CMS, 2019-2025
15 companies · $1,131 in 2025
The $1,131 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $152 · 2021: $122 · 2022: $12.15 · 2023: $49.26 · 2024: $615 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.44 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $450.39 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $289.69 | 2020-2025 | Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $280.42 | 2019-2021 | |
| Adma Biomanufacturing LLC | $151.30 | 2024 | |
| Galderma Laboratories, L.P. | $150.00 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $124.99 | 2024 | Joenja |
| Ars Pharmaceuticals Operations, INC. | $123.65 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $121.98 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $115.78 | 2024 | Orladeyo |
| Optinose US, INC. | $110.94 | 2025 | |
| Alk-Abello, INC | $108.37 | 2020 | |
| Csl Behring | $101.60 | 2025 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $98.34 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Circassia INC. | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.